Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography

Journal of Pediatric Gastroenterology and Nutrition

Volumn 33, Issue 1, 2001, Pages 41-46

  Benatar, A ^a   Feenstra, A ^a   Decraene, T ^a   Vandenplas, Y ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Cisapride (plasma concentration); Heart rate; Heart rhythm; Infants; QT interval; QTc

Indexed keywords

CISAPRIDE;

AGE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; ELECTROCARDIOGRAPHY; ELECTROLYTE BALANCE; FEMALE; GASTROESOPHAGEAL REFLUX; HEART RHYTHM; HUMAN; INFANT; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR;

AGE FACTORS; CASE-CONTROL STUDIES; CISAPRIDE; ELECTROCARDIOGRAPHY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HEART RATE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; LONG QT SYNDROME; MALE; POLYSOMNOGRAPHY; PROSPECTIVE STUDIES;

EID: 0034905170     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200107000-00007     Document Type: Article

References (33)

1. Cisapride and fatal arrhythmia
2. Cisapride and torsades de pointes
3. Long QT syndromes and torsade de pointes
4. Normal ECG standards for infants and children
5. An analysis of the time relations of the electrocardiograms
6. The QT interval throughout the first 6 months of life: A prospective study
7. Cisapride and proarrhythmia in childhood
8. Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography
9. Clinical pharmacokinetics of cisapride
10. Cisapride: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders
11. Gastroesophageal reflux, in 509 healthy infants screened for risk of sudden infant death syndrome
12. Pharmacokinetics
13. The measurement of the Q-T interval of the electrocardiogram
14. U wave: Facts, hypotheses, misconceptions, and misnomers
15. The role of cisapride in the treatment of pediatric gastroesophageal reflux
16. The use of cisapride in children
17. Cisapride-induced long QT interval
18. Effects of cisapride on QTc interval in neonates
19. Allongement de l'espace QT sous cisapride chez le nouveau-né et le nourrisson
20. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?
21. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval
22. Utility of QT dispersion combined with the signal-averaged electrocardiogram in detecting patients susceptible to ventricular arrhythmia
23. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
24. Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease
25. Expression of CYP3A in human liver: Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
26. Cisapride biotransformation: Not all CYP3As are created equal
27. Excretion and biotransformation of cisapride in dogs and humans after oral administration
28. The long QT syndrome: Prospective longitudinal study of 328 families
29. Congenital long QT syndrome: Toward molecular dissection of arrhythmia substrates
30. Effects of cisapride on QT interval in children
31. Proarrhythmia associated with cisapride in children
32. QT dispersion in children with ventricular arrhythmia and a structurally normal heart
33. Measurement, interpretation and clinical potential of QT dispersion